A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

1. Is the biology right?

• Somatic driver evidence: yes · BCL2, BTK in B-cell chronic lymphocytic leukemia

  Rule: Open Targets has somatic-mutation evidence for the target in this cancer. Source: Open Targets: BCL2 in B-cell chronic lymphocytic leukemia, 2026-11-11

  Published context: 2.3× relative success for targets with somatic (IntOGen) support in oncology (Minikel et al., Nature 2024, drug programs to 2023). A ratio between groups, not a probability for this program; mostly phase 2 to 3.
• Human genetic evidence: yes · BCL2: germline, somatic; BTK: somatic

  Rule: Any germline or somatic human genetic evidence for the target in this cancer, counted apart from animal-model and literature evidence. Source: Open Targets: BCL2 in B-cell chronic lymphocytic leukemia, 2026-11-11

  Published context: 2.6× relative probability of success, phase 1 to launch, with human genetic support (Minikel et al., Nature 2024, drug programs to 2023). All therapy areas, mostly germline evidence; not a probability for this program.
• Pediatric target: yes · MS4A1 on the FDA list

  Rule: Target is on FDA's Pediatric Molecular Target List (relevant targets); membership alone neither requires nor waives a study. Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
• Haematologic cancer: yes · Haematologic

  Rule: From the indication, or the registry conditions when no indication matches. Source: ClinicalTrials.gov NCT05197192, 2026-11-11

  Published context: Likelihood of approval from phase 1: 7.5% haematologic vs 4.6% solid (BIO / Informa / QLS 2021, 2011–2020). Population-level, not a prediction.

• MS4A1 (via Obinutuzumab): Evidence types in B-cell chronic lymphocytic leukemia: literature, rna_expression, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, europepmc, expression_atlas. · Open Targets: MS4A1 in B-cell chronic lymphocytic leukemia
• BCL2 (via Venetoclax): Evidence types in B-cell chronic lymphocytic leukemia: rna_expression, clinical, literature, genetic_association, somatic_mutation; literature listed separately from human genetics. Datasources: clinical_precedence, gwas_credible_sets, cancer_gene_census, europepmc, expression_atlas. · Open Targets: BCL2 in B-cell chronic lymphocytic leukemia
• BTK (via Acalabrutinib): Evidence types in B-cell chronic lymphocytic leukemia: literature, affected_pathway, somatic_mutation, clinical; literature listed separately from human genetics. Datasources: clinical_precedence, cancer_gene_census, cancer_biomarkers, europepmc. · Open Targets: BTK in B-cell chronic lymphocytic leukemia

• Not loaded on this app yet: Normal-tissue expression in vital organs. Source: Human Protein Atlas (ticket 36).
• Not loaded on this app yet: Pan-essential in cell lines. Source: DepMap (ticket 36).
• Not loaded on this app yet: Approved drug on this target. Source: Drugs@FDA (ticket 30).

2. Can the result be trusted?

• Randomised: yes · Randomised allocation

  Rule: Registry allocation field. Source: ClinicalTrials.gov NCT05197192, 2026-11-11
• Small denominator: no · 202 planned; each patient moves a rate by 100 ÷ 202 = 0.5 points

  Rule: Enrolment under 30; the arithmetic is shown, not a benchmark. Source: ClinicalTrials.gov NCT05197192, 2026-11-11
• Primary endpoint is overall survival: no · Progression-free survival (PFS)

  Rule: A registered primary outcome measure names overall survival. Source: ClinicalTrials.gov NCT05197192, 2026-11-11

  Published context: Non-OS primary endpoint: odds ratio 2.79 for a positive phase 3 (Otsuka 2021, 400 phase 3 oncology trials, to 2020). Shown with the next figure: a surrogate is easier to hit, and often a weak guide to survival.

  Published context: 52% of surrogate-to-OS correlations are low (Prasad 2015, published to 2014). Shown with the figure above.
• Results overdue: no · Primary completion expected 2028-05; not yet due

  Rule: Primary completion (actual) more than 12 months ago and no results posted to the registry. Source: ClinicalTrials.gov NCT05197192, 2026-11-11

• Not loaded on this app yet: Treated and evaluable counts, assessor, confirmed response, follow-up and data cutoff. Source: Readout extraction (ticket 32).
• Not loaded on this app yet: Primary endpoint changed between registry versions. Source: Registry versions in the store (ticket 32).

3. What must it beat?

• Not loaded on this app yet: Control-arm result and approved therapies for the same segment, with label links. Source: Drugs@FDA, FDA labels and readouts (tickets 30, 32).

4. Too crowded, or too late?

• Stopped on this target: 123 terminated, withdrawn or suspended trials of drugs against MS4A1; 6 give no reason. Reasons are quoted as the registry gives them on the target page. · MS4A1: what already stopped

• Not loaded on this app yet: Programs on the target by phase and months behind the leader. Source: Programs and Drugs@FDA (ticket 33).

5. Can it be approved, and stay approved?

• Single-country: yes · All 30 sites in Germany

  Rule: All listed sites are in one country; the share of US sites is shown. Source: ClinicalTrials.gov NCT05197192, 2026-11-11
• EU paediatric investigation plan: yes · EMA/PE/0000182075 (venetoclax, Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue;Treatment of solid malignant tumours): PM: decision on the application for modification of an agreed PIP, 3 Jan 2025; EMEA-001207-PIP06-22 (obinutuzumab, Prevention of cytokine release syndrome induced by anti CD20/CD3 antibodies): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), date not given; EMEA-001207-PIP05-22 (obinutuzumab, Treatment of glomerulonephritis and nephrotic syndrome): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 8 Sept 2023; EMEA-001207-PIP02-19-M01 (obinutuzumab, Treatment of Systemic Lupus Erythematosus (SLE)): PM: decision on the application for modification of an agreed PIP, 10 Aug 2022; +3 more

  Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
• EU orphan designation: yes · EU/3/16/1625 withdrawn 21 Mar 2016: Treatment of mantle cell lymphoma; EU/3/15/1504 withdrawn 19 Jun 2015: Treatment of follicular lymphoma; EU/3/17/1954 withdrawn 12 Dec 2017: Treatment of mantle cell lymphoma; EU/3/16/1766 withdrawn 14 Oct 2016: Treatment of diffuse large B-cell lymphoma; +9 more

  Rule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
• Authorised in the EU: yes · Calquence: authorised since 5 Nov 2020; Venclyxto: authorised since 4 Dec 2016; Gazyvaro: authorised since 22 Jul 2014

  Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
• FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the link

  Rule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
• FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of Obinutuzumab, Venetoclax, Acalabrutinib

  Rule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
• Registered studies open to children: yes · 121 interventional studies of Obinutuzumab, Venetoclax, Acalabrutinib include patients under 18; 92 are recruiting, not yet recruiting or active

  Rule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11

• Caveat: Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where the sites are is a fact about the record, not a judgement of its quality.
• Cited case: In February 2022 FDA asked its Oncologic Drugs Advisory Committee whether sintilimab's application, resting on ORIENT-11, a phase 3 run only in China, needed further trials showing it applies to US patients and US practice. One case, not a rule. · FDA, ODAC 10 Feb 2022, draft questions
• Rare pediatric disease voucher: FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. · FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs

• Not loaded on this app yet: Precedent approvals for target, modality and endpoint; accelerated-approval status. Source: Drugs@FDA and FDA accelerated-approval tables (ticket 30).

6. Can the sponsor finish?

• Sponsor: German CLL Study Group (academic or other) · ClinicalTrials.gov NCT05197192
• principal investigator: Barbara Eichhorst, MD, Prof., Department I of Internal Medicine, University Hospital Cologne · Person page

• Not loaded on this app yet: Filed cash, quarterly spend and the runway arithmetic. Source: SEC XBRL company facts (ticket 37).
• Not loaded on this app yet: Sponsor's completed vs stopped oncology trials and results-reporting record. Source: Registry, by company (ticket 37).

What public data cannot tell you

Public records cannot show: sales forecasts; a probability of success for this asset; full deal terms and net prices; FDA designations and action dates before approval (shown only as company-reported); clinical holds unless the company disclosed them; manufacturing; patents on unapproved drugs; whether preclinical findings have been replicated.